Baxter International Inc.'s (NYSE: BAX) stock soared 8.24% in the intraday trading session on Thursday, following the company's impressive fourth-quarter 2024 results and a robust outlook for 2025.
The medical products company reported better-than-expected earnings for the fourth quarter, with adjusted earnings per share of $0.77 surpassing the consensus estimate of $0.52. Revenue of $2.75 billion also beat analysts' expectations of $2.67 billion, driven by solid demand across its product portfolio.
Baxter's strong performance has boosted investor confidence, as the company provided an optimistic outlook for 2025. The company expects sales growth from continuing operations of 5% to 6% on a reported basis, and 4% to 5% on an operational basis. Additionally, Baxter projected adjusted earnings from continuing operations, before special items, to range between $2.45 and $2.55 per diluted share, exceeding the consensus estimate of $2.47.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.